Lipid Disorder Treatment Market Report 2024: Demand, Growth Challenges And Forecasts To 2033

The new report published by The Business Research Company, titled Lipid Disorder Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the lipid disorder treatment market size has grown rapidly in recent years. It will grow from $9.48 billion in 2023 to $10.69 billion in 2024 at a compound annual growth rate (CAGR) of 12.7%. The lipid disorder treatment market size is expected to see rapid growth in the next few years. It will grow to $17.36 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15600&type=smp

Impact Of Obesity And High Cholesterol On The Lipid Disorder Treatment Market
The growing cases of obesity and high cholesterol are expected to propel the growth of the lipid disorder treatment market going forward. Obesity is a condition characterized by excessive body fat accumulation, while high cholesterol refers to elevated levels of cholesterol in the blood, which pose significant health risks. Obesity and high cholesterol are on the rise due to unhealthy diets, sedentary lifestyles, genetic predispositions, and environmental influences. Lipid disorder treatment plays a pivotal role in controlling obesity and high cholesterol by combining pharmacological interventions with lifestyle modifications, weight management strategies, patient education, and multidisciplinary care. For instance, in May 2022, according to the World Obesity Atlas 2022, published by the World Obesity Federation, a UK-based non-profit organization, one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030, and that number will increase to 4 billion people, or 51% of the global population, by 2035. Therefore, the growing cases of obesity and high cholesterol are driving the growth of the lipid disorder treatment market.

Innovative Products And Developments In The Management Of Lipid Disorders
Major companies operating in the lipid disorder treatment market are developing proprotein convertase subtilisin type 9 (PCSK9) inhibitors to address the need for more effective and targeted therapies in managing high cholesterol levels. PCSK9 inhibitors manage lipid disorders by enhancing the removal of LDL cholesterol from the bloodstream, thereby reducing the risk of cardiovascular events in high-risk patients. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received approval for Praluent (alirocumab) injection from the U.S. Food and Drug Administration (FDA) to address heterozygous familial hypercholesterolemia (HeFH) in children aged 8 and above. The unique feature of Praluent injection lies in its ability to block the binding of PCSK9 to the LDL receptor, enhancing the quantity of LDL receptors on liver cell surfaces, consequently facilitating the clearance of LDL and reducing LDL-C levels in the bloodstream.

The lipid disorder treatment market covered in this report is segmented -

1) By Drug Type: Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, Other Drugs
2) By Indication: Familial Combined Hyperlipidemia, Familial Defective Apolipoprotein B-100, Familial Dysbetalipoproteinemia, Familial Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @ https://www.thebusinessresearchcompany.com/Discount?id=15600&type=discount

Major companies operating in the lipid disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Fresenius SE & Co. KGaA, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline Plc, Wockhardt Ltd., Eli Lilly and Company, Amgen Inc., Boehringer-Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Kaneka Corporation, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Kowa Pharmaceuticals America Inc., Concord Biotech Limited, Biocon Ltd., Ranbaxy Laboratories Limited

Contents of the report:
1. Executive Summary
2. Lipid Disorder Treatment Market Report Structure
3. Lipid Disorder Treatment Market Trends And Strategies
4. Lipid Disorder Treatment Market - Macro Economic Scenario
5. Lipid Disorder Treatment Market Size And Growth
…..
27. Lipid Disorder Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/lipid-disorder-treatment-global-market-report

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.